Loading company…
MitoImmune Therapeutics develops treatments targeting mitochondrial dysfunction and related diseases.
MitoImmune Therapeutics develops treatments for mitochondrial dysfunction-related necrosis and inflammatory diseases. Established in 2018 and based in Seoul, South Korea, the company licensed technology from LG Chem and is conducting domestic and global Phase 2 trials for oral mucositis in HNSCC patients and an HSCT pre-conditioning regimen.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in